Alex Z Fu1,2, Kristi D Graves3,4, Roxanne E Jensen3,4, John L Marshall4, Margaret Formoso4, Arnold L Potosky3,4. 1. Department of Oncology, Georgetown University, Washington, DC, USA. zf54@georgetown.edu. 2. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3300 Whitehaven Street, NW, Suite 4100, Washington, DC, 20007, USA. zf54@georgetown.edu. 3. Department of Oncology, Georgetown University, Washington, DC, USA. 4. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3300 Whitehaven Street, NW, Suite 4100, Washington, DC, 20007, USA.
Abstract
PURPOSE: Some medical treatment for metastatic colorectal cancer (CRC) may have marginal survival benefit, but cause toxicities. The purpose of this study is to determine metastatic CRC patients' tradeoffs in making a decision to undergo new medical treatment. METHODS: We conducted a survey of patients with a diagnosis of advanced CRC who were currently receiving or completed one chemotherapy regimen. First, patients were asked to rate the importance of 15 medical treatment-related adverse events that may arise as a consequence of chemotherapy or biological therapy in their treatment decision-making. Then, the patient identified his or her top five most important events and solicited preferences in hypothetical metastatic CRC treatment vignettes using the standard gamble technique. RESULTS: A total of 107 patients responded to the survey. From the list of medical treatment-related adverse events, patients identified clinically serious ones such as stroke, heart attack, and gastrointestinal perforation as the most important in their medical treatment decision-making, yet placed lower willingness to tolerate symptom-related events such as pain, fatigue, and depression. Generally, patients who were older, stage III versus IV and who had prior radiotherapy, lower educational attainment, and lower household income (all p <0.05) were less willing to tolerate any medical treatment-related adverse events after adjusting for other demographic and clinical characteristics. CONCLUSIONS: Variations in patients' willingness to tolerate different treatment-related adverse events underscore the need for improved communications between physicians and patients about the risks and benefits of their medical treatment, which helps make a more personalized decision for metastatic CRC treatment.
PURPOSE: Some medical treatment for metastatic colorectal cancer (CRC) may have marginal survival benefit, but cause toxicities. The purpose of this study is to determine metastatic CRC patients' tradeoffs in making a decision to undergo new medical treatment. METHODS: We conducted a survey of patients with a diagnosis of advanced CRC who were currently receiving or completed one chemotherapy regimen. First, patients were asked to rate the importance of 15 medical treatment-related adverse events that may arise as a consequence of chemotherapy or biological therapy in their treatment decision-making. Then, the patient identified his or her top five most important events and solicited preferences in hypothetical metastatic CRC treatment vignettes using the standard gamble technique. RESULTS: A total of 107 patients responded to the survey. From the list of medical treatment-related adverse events, patients identified clinically serious ones such as stroke, heart attack, and gastrointestinal perforation as the most important in their medical treatment decision-making, yet placed lower willingness to tolerate symptom-related events such as pain, fatigue, and depression. Generally, patients who were older, stage III versus IV and who had prior radiotherapy, lower educational attainment, and lower household income (all p <0.05) were less willing to tolerate any medical treatment-related adverse events after adjusting for other demographic and clinical characteristics. CONCLUSIONS: Variations in patients' willingness to tolerate different treatment-related adverse events underscore the need for improved communications between physicians and patients about the risks and benefits of their medical treatment, which helps make a more personalized decision for metastatic CRC treatment.
Authors: Lauris C Kaldjian; Ann E Curtis; Laura A Shinkunas; Katrina T Cannon Journal: Am J Hosp Palliat Care Date: 2008 Dec-2009 Jan Impact factor: 2.500
Authors: Anne Walling; Karl A Lorenz; Sydney M Dy; Arash Naeim; Homayoon Sanati; Steven M Asch; Neil S Wenger Journal: J Clin Oncol Date: 2008-08-10 Impact factor: 44.544
Authors: Natasha B Leighl; Heather L Shepherd; Phyllis N Butow; Stephen J Clarke; Margaret McJannett; Philip J Beale; Nicholas R C Wilcken; Malcolm J Moore; Eric X Chen; David Goldstein; Lisa Horvath; Jennifer J Knox; Monika Krzyzanowska; Amit M Oza; Ronald Feld; David Hedley; Wei Xu; Martin H N Tattersall Journal: J Clin Oncol Date: 2011-04-11 Impact factor: 44.544
Authors: Toni K Choueiri; Erica L Mayer; Youjin Je; Jonathan E Rosenberg; Paul L Nguyen; Georges R Azzi; Joaquim Bellmunt; Harold J Burstein; Fabio A B Schutz Journal: J Clin Oncol Date: 2011-01-04 Impact factor: 44.544
Authors: Alexi A Wright; Baohui Zhang; Alaka Ray; Jennifer W Mack; Elizabeth Trice; Tracy Balboni; Susan L Mitchell; Vicki A Jackson; Susan D Block; Paul K Maciejewski; Holly G Prigerson Journal: JAMA Date: 2008-10-08 Impact factor: 56.272
Authors: Mark R Middleton; Michael B Atkins; Kaitlan Amos; Peter Feng Wang; Srividya Kotapati; Javier Sabater; Kathleen Beusterien Journal: BMC Cancer Date: 2017-10-17 Impact factor: 4.430
Authors: Hiba El Masri; Treasure M McGuire; Mieke L van Driel; Helen Benham; Samantha A Hollingworth Journal: Patient Prefer Adherence Date: 2022-09-20 Impact factor: 2.314